相关实验视频

Updated: Jan 9, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

用赛马格卢提德或蒂尔泽帕提德治疗体重中性的影响db/db小鼠的β细胞身份

Zhaobin Deng¹, Dongxu Zheng², Jinsook Son¹

¹Naomi Berrie Diabetes Center and Department of Medicine, Vagelos College of Physicians & Surgeons of Columbia University, New York, New York, USA.

Acta physiologica (Oxford, England)

|December 7, 2025

概括

在2型糖尿病模型中,塞马格卢提德和蒂尔泽帕提德降低葡萄糖,但不会逆转胰腺β细胞脱差. 这些药物改善胰岛素水平,但没有恢复db/db小鼠中的β细胞身份.

科学领域:

内分泌学在内分泌学.
代谢疾病代谢疾病
分子生物学分子生物学

背景情况:

2型糖尿病 (T2D) 涉及胰岛素抵抗和胰腺β细胞衰竭.
在T2D中,β细胞功能障碍与细胞身份丧失 (脱差/转差) 有关.
以前的研究表明β细胞脱差是可逆的,恢复胰岛素分泌.

研究的目的:

为了研究是否semaglutide或tirzepatide可以逆转db/db小鼠的早期β细胞脱差.
要确定这些影响是否独立于体重变化.
评估对β细胞身份和功能的影响.

主要方法:

db/db小鼠接受了四周的塞马格卢提德或蒂尔泽帕提德治疗.
评估包括口服葡萄糖耐受性测试,免疫光,体重,血糖和血胰岛素监测.
进行了小岛的大量RNA测序,以确定分子标.

主要成果:

蒂尔泽帕提德稳定了体重增加; 塞马格卢提德没有逆转体重增加.
这两种药物都改善了葡萄糖耐受性,并增加了胰岛素水平.
两种药物都没有逆转β细胞脱差 (ALDH1A3+细胞,FOXO1转位) 或正常化PDX1表达.
基因表达分析揭示了无明确目标的沉默转录反应.

结论:

塞马格卢提德和蒂尔泽帕提德在db/db小鼠中显示出早期降血糖效应.
这些对葡萄糖代谢的有益影响独立于β细胞身份的变化.
该研究没有发现这些药物逆转β细胞脱分的证据.

关键词:

在这种情况下,胰岛素胰岛素.塞马格卢提德 (semaglutide) 是一种可怕的药物.这就是Tirzepatide.2 型糖尿病 2 型糖尿病 β-细胞脱差分化的过程.

更多相关视频

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...